I have no disclosures. Disclosures

Similar documents
DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE

Summary/Key Points Introduction

Heart Failure Medical and Surgical Treatment

2016 Update to Heart Failure Clinical Practice Guidelines

State-of-the-Art Management of Chronic Systolic Heart Failure

Heart Failure Update John Coyle, M.D.

Heart Failure (HF) Treatment

Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -

Congestive Heart Failure: Outpatient Management

Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation

Checklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Heart Failure: Guideline-Directed Management and Therapy

The ACC Heart Failure Guidelines

Heart Failure Management Policy and Procedure Phase 1

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014

Saudi Heart Failure Guidelines. Waleed AlHabeeb, MD, MHA Consultant Heart Failure Cardiologist President of the Saudi Heart Failure Group

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)

What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE. Marc Ferrini (Lyon Fr)

Heart Failure. Jay Shavadia

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Heart Failure CTSHP Fall Seminar

Heart Failure. Dr. William Vosik. January, 2012

What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine

Management Strategies for Advanced Heart Failure

Innovation therapy in Heart Failure

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Long-Term Care Updates

Heart Failure Clinician Guide JANUARY 2016

Heart Failure Treatments

Heart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist

Heart Failure: Combination Treatment Strategies

Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary

Guideline-Directed Medical Therapy

Module 1: Evidence-based Education for Health Care Professionals

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 10/5/2015. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center

Heart Failure Clinician Guide JANUARY 2018

CLINICAL PRACTICE GUIDELINE

Advanced Care for Decompensated Heart Failure

Module 1: Evidence-based Education for Health Care Professionals

Therapeutic Targets and Interventions

CKD Satellite Symposium

Heart Failure Challenges and Unmet needs

Antialdosterone treatment in heart failure

CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD

HFpEF. April 26, 2018

Chronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH

Outline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

The Failing Heart in Primary Care

Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham

WHAT S NEW IN HEART FAILURE

2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 2/20/2017. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Heart Failure Management: Continuum of Care

Outline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies

Introduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL

Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Definition of Congestive Heart Failure

HEART FAILURE. Study day November 2017 Sarah Briggs and Janet Laing

Heart Failure 101 The Basic Principles of Diagnosis & Management

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

Incidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction

Sliwa et al. JACC 2004;44:

Diastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012

Objectives. Heart failure and Hypertension. Definition & epidemiology of heart failure HEART FAILURE 3/12/2016. Kirsten Bibbins-Domingo, PhD, MD, MAS

Heart Failure Background, recognition, diagnosis and management

Pathophysiology: Heart Failure

Heart Failure A Team Approach Background, recognition, diagnosis and management

Topic Page: congestive heart failure

Practice-Level Executive Summary Report

Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management

NICE Chronic Heart Failure Guidelines in Adults 2018

Device Therapy for Heart Failure

Heart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid

Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists

Initiating New Medications in the Management of Heart Failure

ESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309

MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)

Congestive Heart Failure 2015

Combination of renin-angiotensinaldosterone. how to choose?

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.

Balanced information for better care. Heart failure: Managing risk and improving patient outcomes

Medical Therapy after LVAD

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008

Heart Failure Overview. Dr Chris K Y Wong

2014 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure

Epidemiology of Symptomatic Heart Failure in the U.S.

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

PRESS RELEASE. New NICE guidance will improve diagnosis and treatment of chronic heart failure

Heart Failure Therapies State of the Art: 2018

Transcription:

I have no disclosures Disclosures

What is Heart Failure? Heart Failure (HF) A complex clinical syndrome where patients present with symptoms (i.e. dyspnea, fatigue, fluid retention) that result from any structural or functional impairment of ventricular filling or ejection of blood

Two Types of HF HFpEF (heart failure with preserved ejection fraction) Clinical diagnosis of HF LVEF 50% Impaired filling HFrEF (heart failure with reduced ejection fraction) Clinical diagnosis of HF LVEF 40% Impaired contractility

The End of All Things Myocarditis Valve disease Hypertension CAD Heart Failure Toxins

Impact of Heart Failure Affects > 5.8 million Americans 20% lifetime risk for those over the age of 40 Prognosis is poor: 40% 5 year survival Similar to lung cancer >3 million hospitalizations yearly in US 1-month re-hospitalization rate of 25% (lower at UCD ) Cost per hospitalization = $23,000 HF care in US exceeds $30 billion yearly

Initial Therapy Identify underlying causes and treat Revascularization of severe coronary disease Valve repair/replacement Treat arrhythmias Cessation of toxins Correct metabolic disorders General measures

Three Pillars of Treatment Best Possible Outcome Lifestyle Modification Medication Devices Adherence Education

Lifestyle Modification Low Salt Diet Extreme salt restriction may be harmful 2000 mg sodium/day Fluid Restriction 2 liters/day of all fluids Activity Encouraged

Cardiac Rehabilitation HF-ACTION trial Large randomized controlled trial of cardiac rehabilitation vs. usual care in HFrEF patients 13% reduction in all cause mortality or hospitalization Now reimbursed by CMS LVEF 35% NYHA Class II-IV Symptoms Stable for 6 weeks (i.e. not hospitalized for HF) No procedures planned

Pills All of the clinical trials have only shown benefit of the traditional heart failure medications in HFrEF Evidence based HFpEF medical therapy is lacking

HFrEF Medications: The Essentials Heart Failure beta blocker (BB) Bisoprolol, Carvedilol, Metoprolol Succinate Studied in clinical trials and demonstrated survival benefit ACE inhibitor Angiotensin receptor blocker (ARB) If ACE inhibitor intolerant Aldosterone antagonist Hydralazine/isordil If patient is self-described as African-american

Medications BB, ACE I, ARB, Aldosterone antagonist Target maladaptive neurohormonal pathways that are upregulated in heart failure May aid in recovery of myocardium or beneficial remodeling Reduce myocardial fibrosis Survival benefit

Medications: Use as needed Loop diuretics No clinical trials to prove survival benefit Digoxin Antiarrhythmic medications Amiodarone and dofetilide Thiazide diuretics Vasopressin antagonist Inotropic therapy

Medications to Avoid NSAIDS Decongestants Thiazolidinediones Non-dihydropyridine calcium channel blockers Nutritional supplements

Devices

Defibrillators Primary prevention of sudden cardiac death LVEF 35% NYHA Class II-III Optimal medical therapy Survival benefit, but no symptomatic relief

Other Defibrillators

Cardiac Resynchronization Therapy (CRT) Commonly placed with ICD Left ventricular epicardial lead added Best for patients who meet ICD criteria and have a wide QRS or anticipated high right ventricular pacing burden Symptomatic benefit

Left Ventricular Assist Devices (LVAD) For end stage heart failure Durable devices Mechanical pumps that impel blood from left ventricle to aorta Newer devices are continuous flow Patients can go home with the pump

Continuous Flow LVAD Heartmate II (Thoratec) Rotating impellers with minimal bearings Left sided support only Single moving part Implanted by median sternotomy

Accessories/Other Equipment

Miniaturization of Devices Circulite

Education Multidisciplinary approach recommended Tailor education to patient Individual and group interface Low health literacy materials available Teach back method

Adherence Identify barriers Financial, psychosocial, motivational ( what s the point? ), organizational, cognitive Tools Pillboxes, bubble packs Home health Motivational interviewing Assisted living, etc.

Summary Heart failure arises from many different possible disease states or causes Treatment is based on physiology and disease severity Three pillars of treatment: lifestyle modification, medication, devices Patient education and adherence to care plan are essential to promote successful heart failure management